Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention for bifurcation lesions.
Raffaele PiccoloGiovanni EspositoPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
Ticagrelor monotherapy after a short course of aspirin is emerging as the predominant aspirin-free strategy among patients undergoing percutaneous coronary intervention. In patients included in the GLOBAL-LEADERS trial, the treatment effect of the experimental (dual antiplatelet therapy with aspirin and ticagrelor for 1 month followed by ticagrelor monotherapy) versus control strategy remained consistent irrespective of the presence or absence of coronary bifurcation. Ticagrelor monotherapy represents a safe and effective antiplatelet strategy for the treatment of patients who undergo percutaneous coronary intervention of bifurcation lesions.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- coronary artery disease
- st elevation myocardial infarction
- combination therapy
- acute myocardial infarction
- patients undergoing
- coronary artery bypass grafting
- open label
- atrial fibrillation
- coronary artery bypass
- end stage renal disease
- low dose
- cardiovascular events
- clinical trial
- newly diagnosed
- heart failure
- ejection fraction
- endovascular treatment
- left ventricular
- peritoneal dialysis
- randomized controlled trial
- phase iii
- smoking cessation